Unlocking the Potential of NDUFS6 as a Drug Target: Unraveling the Complex I Mitochondrial Respiratory Chain

Target Name: NDUFS6

NCBI ID: G4726

NDUFS6

Unlocking the Potential of NDUFS6 as a Drug Target: Unraveling the Complex I Mitochondrial Respiratory Chain

Introduction

The mitochondrial respiratory chain is a critical enzyme system that generates the majority of the energy for the cell during the respiration process. The complex I (NAD+-dependent respiratory chain) is the primary pathway for generating energy in the cell, and it is a well-established drug target for various diseases, including cancer, neurodegenerative disorders, and metabolic diseases. The 13-kD subunit, also known as NDUFS6, is a key component of the complex I and has been identified as a potential drug target due to its unique structure, function, and regulation.

Structure and Function of NDUFS6

The NDUFS6 protein is a 13-kD subunit of the complex I mitochondrial respiratory chain. It consists of 64 amino acids and has a calculated pI of 9.35. The protein has a unique 尾-sheet structure, which is rare in the context of the mitochondrial respiratory chain. The 尾-sheet is involved in the formation of a distinct 尾-尾 interaction and is responsible for the stability and functional relevance of the protein.

NDUFS6 is a critical component of the complex I, as it plays a crucial role in the electron transport process. It functions as a subunit of the E2 subunit, which is responsible for the transfer of electrons from the cytoplasm to the mitochondrial matrix during the final step of the electron transport chain. The E2 subunit is the most abundant subunit of the complex I and has been the focus of much research due to its potential as a drug target.

Drug Target Potential

The unique structure and function of NDUFS6 make it an attractive drug target. The 尾-sheet and its distinct 尾-尾 interaction have been reported to play a crucial role in the stability and functional relevance of the protein. Additionally, the NDUFS6 protein has been shown to have a direct impact on the levels of mitochondrial energy production during the electron transport process.

Several studies have investigated the potential ofNDUFS6 as a drug target. For instance, in cancer cells, increased levels of NDUFS6 have been observed, which may contribute to the energetic demand of these cells and contribute to their enhanced survival. Similarly, in neurodegenerative disorders, NDUFS6 has been shown to be involved in the progression of neurodegeneration and has been considered as a potential therapeutic target.

Conclusion

In conclusion, NDUFS6 is a unique protein that plays a crucial role in the mitochondrial respiratory chain and has been identified as a potential drug target due to its unique structure, function, and regulation. The 尾-sheet and its distinct 尾-尾 interaction have has been shown to play a crucial role in the stability and functional relevance of the protein. Further research is needed to fully understand the potential of NDUFS6 as a drug target and to explore its therapeutic potential in various diseases.

Protein Name: NADH:ubiquinone Oxidoreductase Subunit S6

Functions: Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

The "NDUFS6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDUFS6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets